Guardant Health Inc
NASDAQ:GH

Watchlist Manager
Guardant Health Inc Logo
Guardant Health Inc
NASDAQ:GH
Watchlist
Price: 35.1 USD 2.12% Market Closed
Market Cap: 4.3B USD
Have any thoughts about
Guardant Health Inc?
Write Note

Guardant Health Inc
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Guardant Health Inc
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
Guardant Health Inc
NASDAQ:GH
Total Other Income
$73.8m
CAGR 3-Years
295%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
DaVita Inc
NYSE:DVA
Total Other Income
-$61.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Quest Diagnostics Inc
NYSE:DGX
Total Other Income
$10m
CAGR 3-Years
-70%
CAGR 5-Years
27%
CAGR 10-Years
9%
CVS Health Corp
NYSE:CVS
Total Other Income
$96m
CAGR 3-Years
-21%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Cigna Corp
NYSE:CI
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Laboratory Corporation of America Holdings
NYSE:LH
Total Other Income
$84.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
21%
No Stocks Found

Guardant Health Inc
Glance View

Market Cap
4.3B USD
Industry
Health Care

Guardant Health, Inc. is a precision oncology company, engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Redwood City, California and currently employs 1,373 full-time employees. The company went IPO on 2018-10-04. The firm is focused on helping conquer cancer through the use of its blood-based tests, data sets, and advanced analytics. The company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. The company also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need for Stage II-II I colorectal cancer. Its Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes. Its Guardant360 CDx test is a liquid biopsy test measuring 55 cancer-related genes. Its GuardantOMNI test has a broader 500-gene panel, all of which analyze circulating tumor deoxyribonucleic acid (DNA) in the blood. The firm's tests are used by biopharmaceutical companies for a range of applications, including identifying patient populations to accelerate translational science research and clinical trial enrollment, and companion diagnostic.

GH Intrinsic Value
34.89 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Guardant Health Inc's Total Other Income?
Total Other Income
73.8m USD

Based on the financial report for Sep 30, 2024, Guardant Health Inc's Total Other Income amounts to 73.8m USD.

What is Guardant Health Inc's Total Other Income growth rate?
Total Other Income CAGR 3Y
295%

Over the last year, the Total Other Income growth was 7 281%. The average annual Total Other Income growth rates for Guardant Health Inc have been 295% over the past three years .

Back to Top